Point72 Asset Management
KYNB

Point72 Asset Management’s Kyntra Bio KYNB Stock Holding History

Point72 Asset Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-64,000
Closed -$1.42M – 2316
2023
Q4 		$1.42M Hold
64,000
– – ﹤0.01% 1302
2023
Q3 		$1.38M Sell
64,000
-20,000
-24% -$785K ﹤0.01% 1233
2023
Q2 		$5.67M Buy
84,000
+20,000
+31% +$8.27M 0.02% 778
2023
Q1 		$29.9M Buy
64,000
+4,000
+7% +$2.12M 0.09% 263
2022
Q4 		$24M Hold
60,000
– – 0.08% 292
2022
Q3 		$19.5M Hold
60,000
– – 0.08% 329
2022
Q2 		$15.8M Buy
+60,000
New +$15.3M 0.07% 373

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Point72 Asset Management's KYNB Position: Q2 2024 in Review

Point72 Asset Management sold out of Kyntra Bio (KYNB) in Q2 2024, closing a stake of 43,211 shares — an estimated $2.54M sold.

Point72 Asset Management first reported a position in KYNB in Q3 2021 and held it in 9 quarters. The position peaked at $76.6M in Q4 2022. 102 funds tracked by Wall St. Rank hold KYNB as of Q2 2024.

  • Point72 Asset Management reported no remaining Kyntra Bio position as of Q2 2024 after selling out during the quarter.
  • Point72 Asset Management sold 43,211 Kyntra Bio shares in Q2 2024, an estimated $2.54M.
  • Point72 Asset Management first reported a position in Kyntra Bio in Q3 2021 and held it in 9 quarters.
  • Point72 Asset Management's Kyntra Bio position peaked at $76.6M in Q4 2022.
  • 102 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2024.

Based on Point72 Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.